
Guru P. Sonpavde, MD
@sonpavde
Followers
4K
Following
15K
Media
176
Statuses
1K
Phase I+GU Oncology Director @AdventHealthCFL #Cancer Institute, Prof. @ucf Orlando, #Florida, #ASCO, #ESMO, #AACR, Following/Retweet ≠ endorsement, Views mine
Orlando, FL, USA
Joined March 2014
Pleased to comment on #ASCO25 urologic medical oncology highlights #prostatecancer #kidneycancer #bladdercancer on @doximity from @adventhealth @AdventHealthCFL #cancer Institute, Orlando, #Florida.
0
0
7
#ASCO25 GU #cancer highlights- pleased to comment in @doximity from @AdventHealthCFL @AdventHealth @DrYukselUrun @drenriquegrande @neerajaiims @montypal @shilpaonc .
opmed.doximity.com
Practice-changing data
1
7
27
RT @cure_today: Breaking Down the CheckMate 901 Trial Data for Metastatic Bladder Cancer @sonpavde @AdventHealth @ASCO #ASCO25 #MedTwitter….
curetoday.com
Dr. Guru Sonpavde discusses the CheckMate 901 trial evaluating Opdivo plus Yervoy for those with cisplatin-ineligible, metastatic urothelial carcinoma.
0
3
0
RT @OncLive: Always a pleasure to speak with @sonpavde of @AdventHealth and our conversation at #ASCO25 was no different! Hear Dr Sonpavde….
0
4
0
#bladdercancer perioperative therapy - pleased to comment in @EuropeanUrology Focus - Perioperative durvalumab (ie not just neoadjuvant) combined with neoadjuvant cisplatin-based chemotherapy should be the current preferred strategy for most patients with muscle-invasive disease.
0
2
18
RT @neerajaiims: Ab#4500 @ASCO #ASCO25 by @MichvdHeijden👉�IPI+NIVO vs Gem+Carbo in ph 3 CheckMate 901 trial in cis-i….
0
29
0
Honored to participate from @AdventHealthCFL #cancer Institute, Orlando, #Florida and @DanaFarberNews @DanaFarber_GU.
Thrilled to share our new analysis from CheckMate 901!.🟡In N+ only metastatic UC, Nivolumab + chemo doubled complete response rate vs chemo alone (63% vs 34%) and prolonged PFS (HR 0.38) and OS (HR 0.58). ➡️A new horizon for a distinct subgroup. @EUplatinum @OncoAlert
0
2
17
#bladdercancer systemic #immunotherapy biomarker paper in @jitcancer @sitcancer: Pre-emptive identification of patients at high risk of primary refractory disease on any systemic therapy is challenging but necessary to enable an early switch to other treatment choices before.
0
1
6
#AACR25 @AACR pleased to preview #clinicaltrial highlights of developmental therapeutics across solid tumors - and #bladdercancer #ProstateCancer #kidneycancer - from @AdventHealthCFL @AdventHealth.
1
4
17
RT @OncLive: WATCH: @sonpavde of @AdventHealthCFL discusses the INTerpath-005 study evaluating adjuvant V940 plus pembrolizumab in resected….
onclive.com
Guru P. Sonpavde, MD, discusses the INTerpath-005 study evaluating adjuvant V940 plus pembrolizumab in resected high-risk MIBC.
0
1
0
#AACR25 #clinicaltrial highlights - looking forward to highlighting from @AdventHealthCFL #cancer Institute @UCFMed.
@AACR 2025: The regular abstracts and late-breaking, clinical trials titles are here. Follow us for the latest updates and insights. #LARVOL #AACR25 #Oncology #CancerResearch #OncologyInsights #CancerData #ClinicalTrials | @LARVOL. Connect with some of the top voices on X from
1
0
15
RT @CParkMD: ⭐️ Loved this tough case presentation below by Dr. Priyanka Chablani. @PriyankaChabla1.Great discussion with @sonpavde @MattM….
0
8
0
RT @GUOncologyNow: 📺 A virtual roundtable hosted by @PGrivasMDPhD contextualized the latest #bladdercancer research updates and trials of r….
0
4
0
#GU25 #bladdercancer commentary: PD1/L1 Inhibitor Therapy for Muscle-Invasive Bladder Cancer: Adjuvant or Neoadjuvant + Adjuvant?" Pleased to comment from @AdventHealthCFL #cancer Institute- @OncoAlert @DrYukselUrun @drenriquegrande @shilpaonc @AndreaNecchi @MattGalsky.
1
4
20
#GU25: Key #bladdercancer presentations (in my opinion)- highlights and summary coming after the conference from @AdventHealthCFL #cancer Institute- please note @OncoAlert @Larvol @OncLive @GUOncologyNow @SWOG @DrNeilLove @PeerView @doximity
2
30
83